Armistice Capital LLC Has $25.88 Million Holdings in Grifols, S.A. $GRFS

Armistice Capital LLC grew its holdings in Grifols, S.A. (NASDAQ:GRFS) by 23.8% during the fourth quarter, Holdings Channel.com reports. The firm owned 2,768,000 shares of the biotechnology company’s stock after acquiring an additional 532,000 shares during the quarter. Armistice Capital LLC’s holdings in Grifols were worth $25,881,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of GRFS. Bank of Montreal Can boosted its position in Grifols by 3,205.1% during the third quarter. Bank of Montreal Can now owns 3,013,723 shares of the biotechnology company’s stock valued at $30,017,000 after purchasing an additional 2,922,540 shares during the last quarter. Arrowstreet Capital Limited Partnership boosted its position in Grifols by 383.7% during the third quarter. Arrowstreet Capital Limited Partnership now owns 2,800,645 shares of the biotechnology company’s stock valued at $27,894,000 after purchasing an additional 2,221,633 shares during the last quarter. Norges Bank acquired a new position in Grifols during the fourth quarter valued at approximately $18,139,000. Brandes Investment Partners LP boosted its position in Grifols by 6.3% during the fourth quarter. Brandes Investment Partners LP now owns 30,954,223 shares of the biotechnology company’s stock valued at $289,422,000 after purchasing an additional 1,838,727 shares during the last quarter. Finally, Barclays PLC boosted its position in Grifols by 132.6% during the fourth quarter. Barclays PLC now owns 2,434,636 shares of the biotechnology company’s stock valued at $22,764,000 after purchasing an additional 1,387,783 shares during the last quarter.

Grifols Trading Down 1.7%

NASDAQ GRFS opened at $7.46 on Thursday. The company has a quick ratio of 0.85, a current ratio of 2.47 and a debt-to-equity ratio of 1.16. Grifols, S.A. has a twelve month low of $7.26 and a twelve month high of $11.14. The company has a market cap of $5.08 billion, a price-to-earnings ratio of 39.26, a price-to-earnings-growth ratio of 0.29 and a beta of 0.65. The business’s fifty day moving average is $7.97 and its 200 day moving average is $8.54.

Grifols (NASDAQ:GRFS) last released its quarterly earnings data on Saturday, February 14th. The biotechnology company reported $0.38 earnings per share for the quarter. Grifols had a return on equity of 6.21% and a net margin of 5.54%.The company had revenue of $2.32 billion for the quarter. As a group, sell-side analysts expect that Grifols, S.A. will post 1.06 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the company. Wall Street Zen lowered Grifols from a “buy” rating to a “hold” rating in a research note on Monday, May 18th. Zacks Research lowered Grifols from a “hold” rating to a “strong sell” rating in a research note on Friday, May 8th. Finally, Weiss Ratings upgraded Grifols from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Friday, May 8th. Three analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Reduce” and a consensus target price of $10.00.

About Grifols

Grifols, Inc (NASDAQ: GRFS) is a global healthcare company specializing in the development, manufacture and marketing of plasma-derived medicines, diagnostic systems and hospital supplies. With a core focus on immunotherapy and transfusion medicine, the company harnesses human plasma proteins to create therapies that treat a wide range of bleeding disorders, immunodeficiencies and neurological conditions. Grifols also supplies reagents and diagnostic instruments for transfusion centers and clinical laboratories, alongside intravenous solutions and medical devices for hospital use.

The company operates three main business units.